scholarly journals Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Eoi Jong Seo ◽  
Joo Yong Lee
Keyword(s):  
Treatment Group ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Combined Treatment ◽  
Intravitreal Bevacizumab ◽  
Late Complications ◽  
Refractive Errors ◽  
Retinal Vessels ◽  
Zone Ii

Background/Aim. The aim of the study was to investigate the outcomes of temporal Zone II-sparing laser photocoagulation combined with intravitreal bevacizumab (IVB) in patients with Type 1 retinopathy of prematurity (ROP) in Zone I.Methods. Medical records of 74 eyes of 37 infants were analysed. Only infants with Type 1 ROP in Zone I were included. Thirty-two eyes were treated with temporal-sparing laser + IVB. Both Zone I and temporal Zone II were spared to minimise potential visual field loss. Forty-two eyes were treated with laser alone conventionally. Early treatment outcomes, late complications, and refractive errors were analysed.Results. The mean gestational age and birth weight of the enrolled patients were 25.7 ± 2.5 weeks and 798.8 ± 440.2 g, respectively. In the combined treatment group, plus sign regression was achieved faster (12.1 ± 6.2 days vs. 25.6 ± 21.3 days,p=0.011) and retreatment was required less (0% vs. 23.8%,p=0.004) than in the laser-alone group. Retinal/preretinal haemorrhages occurred more often in the laser-alone group (42.9% vs. 9.4%,p=0.002). Normal development of temporal retinal vessels was also observed in twelve eyes in the combined treatment group. No differences in late complications or refractive errors were observed between the groups.Conclusion. Temporal Zone II-sparing laser treatment combined with IVB showed good early treatment outcome and temporal retinal vessels development.

scholarly journals Transscleral vs transpupillary diode laser photocoagulation for the treatment of zone II type 1 retinopathy of prematurity: Anatomical and refractive outcomes

2022 ◽  
Vol 70 (1) ◽  
pp. 189
Author(s):  
Nazanin Ebrahimiadib ◽  
Ramak Roohipourmoallai ◽  
Shahin Faghihi ◽  
Hooshang Faghihi ◽  
Ali Torkashvand ◽  
...  
Keyword(s):  
Diode Laser ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Refractive Outcomes ◽  
Zone Ii

Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

2020 ◽  
pp. 163-168
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Peripheral Retina ◽  
Controlled Clinical Trial ◽  
Disease Development ◽  
Retinal Vessels ◽  
Randomized Controlled Clinical Trial ◽  
Zone Ii ◽  
Conventional Laser

The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a randomized, controlled clinical trial to determine whether intravitreal bevacizumab monotherapy was an effective therapy for treating zone I or zone II posterior stage 3+ (stage 3 with plus disease) retinopathy of prematurity (ROP). Intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels (with possible recurrence of ROP) continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina.

Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity

2018 ◽  
Vol 103 (4) ◽  
pp. 494-498 ◽  
Author(s):  
Yichen Bai ◽  
Huanjie Nie ◽  
Shiyu Wei ◽  
Xiaohe Lu ◽  
Xiaoyun Ke ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Primary Outcome ◽  
Safety And Efficacy ◽  
Postmenstrual Age ◽  
Zone Ii ◽  
The Mean ◽  
Secondary Outcomes ◽  
Number Of Injections

BackgroundTo evaluate the safety and efficacy of intravitreal conbercept (IVC) injection in the treatment of retinopathy of prematurity (ROP).MethodsPatients with ROP who underwent IVC injection in Zhujiang Hospital from June 2015 to July 2016 were studied retrospectively. The primary outcome was defined as the regression of plus disease. The secondary outcomes were defined as the presence of recurrence, number of injections and the final regression of disease.ResultsA total of 48 eyes of 24 patients with ROP were included. Among them, 9 eyes of 5 patients had zone I ROP, 35 eyes of 18 patients had zone II ROP and 4 eyes of 2 patients had aggressive posterior ROP. The mean gestational age was 28.5±1.6 weeks, the mean birth weight was 1209.6±228.6 g, the mean postmenstrual age of first injection was 34.2±1.9 weeks and the mean follow-up period was 31.0±4.7 weeks. Forty of 48 eyes (83.3%) received IVC only once, and the regression of plus disease occurred at an average of 3.5±1.5 weeks after the first injection of conbercept. For eight recurrent eyes (16.7%), four eyes received a second IVC and the remaining four eyes received laser photocoagulation, and the regression of plus disease occurred in 3 weeks. No lens opacity, vitreous haemorrhage, entophthalmia or retinal detachment was observed during follow-up.ConclusionIVC injection is an effective treatment for ROP.

Delayed Laser photocoagulation following intravitreal anti–vascular endothelial growth factor injection allows immature retinal vessels to regrow without recurrence of retinopathy of prematurity

2019 ◽  
Author(s):  
Ki Yup Nam ◽  
Ji Eun Lee ◽  
Joo Eun Lee ◽  
Hyun Wong Kim ◽  
Sang Joon Lee
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Laser Photocoagulation ◽  
Retinal Vessel ◽  
Disease Recurrence ◽  
Retinal Vessels ◽  
Vascular Endothelial ◽  
Zone Ii ◽  
Vessel Development ◽  
Endothelial Growth Factor

Abstract Purpose: The effects of delayed laser photocoagulation (LP) for ROP patients who received intravitreal anti–vascular endothelial growth factor injections (IVAs) on peripheral vascularization and disease recurrence in ROP patients. Methods: A total of 26 consecutive infant eyes of 14 patients who received IVA treatments were retrospectively investigated. The patients were divided into two groups depending on the initial treatment as follows: IVA group and prompt LP group. Recurrence of ROP, growth of the retinal vessels, and associated complications were evaluated. Results: There were 16 eyes in the IVA group and 10 eyes in the LP group. In the IVA group, delayed LP was performed in six eyes due to recurrences of ROP. In 16 eyes of the IVA group, the retinal vessels grew upto Zone III in eyes received IVA only. Among the IVA groups, Delayed LP was needed in six eyes due to ROP recurrence following IVA. Delayed LP was performed average 7~8 weeks after IVA, which could give the immature neurovascular tissues time to continue vascular development upto Zone II without further ROP recurrence. However, the prompt LP group did not show vessel development beyond the laser scar. Conclusions: Delayed LP following IVA might provide a chance for retinal vessel development in the immature retina to continue without unexpected ROP recurrences.

Sign in / Sign up

Export Citation Format

Share Document